Is there any benefit to adding bevacizumab to chemo-immunotherapy in metastatic NSCLC?

In the ITT population of the Impower 150 trial the median OS was 19.2 mo on arm B (Atezo + chemo + bev) and 14.7 mo on arm C (chemo + bev) with a Significant HR of 0.78 but the mOS in arm A (atezo + chemo) was 19.4 mo with no planned comparison to arm B but seems not to be significant. So the presen...

With further follow-up we may see differences in mOS between arms A+B of IMpower 150 (which may not be surprising given what we know about the addition of bevacizumab to paclitaxel/carboplatin from ECOG 4599), and no statistical comparison of arms A+B was planned as part of this trial. The more rele...

There appears to be early hints that adding bevacizumab may have some role based on the comparative HRs.

In the ITT-WT population, the HR for OS was 0.78 (95% CI 0.64-0.96, p=0.016) with the bev+IO+Chemo arm in relation to control chemo+Bev group compared to HR for OS of 0.88 (95% CI 0.72-1.08, p=0....